Search results for " Fluticasone propionate"

showing 6 items of 6 documents

Effects in cigarette smoke stimulated bronchial epithelial cells of a corticosteroid entrapped into nanostructured lipid carriers

2014

Background Nanomedicine studies have showed a great potential for drug delivery into the lung. In this manuscript nanostructured lipid carriers (NLC) containing Fluticasone propionate (FP) were prepared and their biocompatibility and effects in a human bronchial epithelial cell line (16-HBE) stimulated with cigarette smoke extracts (CSE) were tested. Results Biocompatibility studies showed that the NLC did not induce cell necrosis or apoptosis. Moreover, it was confirmed that CSE increased intracellular ROS production and TLR4 expression in bronchial epithelial cells and that FP-loaded NLC were more effective than free drug in modulating these processes. Finally, the nanoparticles increased…

BiocompatibilityCellBiomedical EngineeringMedicine (miscellaneous)Pharmaceutical ScienceApoptosisBronchiBioengineeringChronic obstructive pulmonary disease; Asthma; hronic obstructive pulmonary disease.PharmacologyFluticasone propionatemedicine.disease_causeApplied Microbiology and BiotechnologyNanostructured lipid carriers Corticosteroid Fluticasone propionate Cigarette smoke Airway epithelial cell Chronic obstructive pulmonary disease Asthmachemistry.chemical_compoundAirway epithelial cellmedicineHumansCorticosteroidCells CulturedFluticasoneDrug CarriersNanostructured lipid carriersbusiness.industryResearchChronic obstructive pulmonary diseaseSmokingCigarette smokeEpithelial CellsGlutathioneGlutathioneLipidsAsthmaNanostructuresToll-Like Receptor 4medicine.anatomical_structurechemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoApoptosisDrug deliveryFluticasoneMolecular MedicineReactive Oxygen SpeciesbusinessOxidative stressIntracellularmedicine.drugJournal of Nanobiotechnology
researchProduct

IκB kinase-driven nuclear factor-κB activation in patients with asthma and chronic obstructive pulmonary disease.

2011

Background Nuclear factor-κB (NF-κB) is a transcriptional factor of different inflammatory patterns involved in asthma and chronic obstructive pulmonary disease (COPD) that is tightly controlled by IκB kinase (IKK) complex. Objective We investigated the dysregulation of IKK-driven NF-κB activation in patients with asthma and COPD. Methods We assessed IKKα and IKKβ expression and activation, their regulation by glucocorticosteroids, and their involvement in IL-8 synthesis in PBMCs isolated from asthmatic patients, healthy smokers (HSs), patients with COPD, and control subjects. PBMCs from control subjects were stimulated with TNF-α and cigarette smoke extract in the presence or absence of fl…

Glutathione-S-transferaseAdultMaleImmunologyInflammationIκB kinaseFluticasone propionateFEV1/FVC ratioPulmonary Disease Chronic ObstructiveImmunopathologymedicineImmunology and AllergyHumansInterleukin 8COPD CSE Fluticasone propionateIKK IκB kinaseGlucocorticoidsAsthmaHDACCOPDbusiness.industryInterleukin-8SmokingNF-kappa BMiddle Agedmedicine.diseaseAsthmaBronchodilator AgentsI-kappa B KinaseEnzyme ActivationGene Expression RegulationNF-κBImmunologyLeukocytes MononuclearFemalemedicine.symptombusinessmedicine.drugThe Journal of allergy and clinical immunology
researchProduct

Clinical and Biological Heterogeneity in Children with Moderate Asthma

2003

To evaluate the relationship between inflammatory markers and severity of asthma in children, the amount of interleukin-8 (IL-8) and granulocyte/macrophage colony-stimulating factor (GM-CSF) released by peripheral blood mononuclear cells, exhaled nitric oxide (FE NO) levels, p65 nuclear factor-kappaB subunit, and phosphorylated IkBalpha expression by peripheral blood mononuclear cells were assessed in six control subjects, 12 steroid-naives subjects with intermittent asthma, and 17 children with moderate asthma. To investigate their predictive value, biomarker levels were correlated with the number of exacerbations during a 18-month follow-up period. We found that GM-CSF release was higher …

MaleExacerbationAnti-Inflammatory AgentsCritical Care and Intensive Care MedicineSynaptotagminsMedicineChildSalmeterol XinafoateCalcium-Binding ProteinMembrane GlycoproteinsRespiratory diseaseNF-kappa Binflammatory markersBronchodilator AgentsAnti-Inflammatory AgentSynaptotagmin IBiomarker (medicine)FemaleMembrane GlycoproteinAndrostadienes; Anti-Inflammatory Agents; NF-kappa B; Leukocytes Mononuclear; Membrane Glycoproteins; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Synaptotagmins; Albuterol; Asthma; Child; Receptors Cell Surface; Nerve Tissue Proteins; Nitric Oxide; Synaptotagmin I; Calcium-Binding Proteins; Interleukin-8; Adolescent; Bronchodilator Agents; Male; Biological Markers; Femalemedicine.symptomHumanmedicine.drugPulmonary and Respiratory MedicineAdolescentNerve Tissue ProteinsReceptors Cell SurfaceInflammationNitric OxidePeripheral blood mononuclear cellFluticasone propionateHumansAlbuterolBronchodilator AgentAsthmaAndrostadienefluticasone propionatebusiness.industryCalcium-Binding ProteinsInterleukin-8Granulocyte-Macrophage Colony-Stimulating Factormedicine.diseaseSynaptotagminAsthmaAndrostadienesasthma; inflammatory markers; fluticasone propionateNerve Tissue ProteinBiological MarkerExhaled nitric oxideImmunologyLeukocytes MononuclearFluticasonebusinessBiomarkersAmerican Journal of Respiratory and Critical Care Medicine
researchProduct

Fluticasone in mild to moderate atopic dermatitis relapse: A randomized controlled trial

2018

Background: The long-term efficacy of corticosteroids to prevent atopic dermatitis (AD) relapses has partially been addressed in children. This study compared an intermittent dosing regimen of fluticasone propionate (FP) cream 0.05% with its vehicle base in reducing the risk of relapse in children with stabilized AD. Methods A randomized controlled, multicentric, double-blind trial was conducted. Children (2-10 years) with mild/moderate AD (exclusion criteria: > 30% affected body surface area and/or head) were enrolled into an Open-label Stabilization Phase (OSP) of up to 2 weeks on twice daily FP. Those who achieved treatment success entered the Double-blind Maintenance Phase (DMP). They w…

MalePulmonary and Respiratory Medicinemedicine.medical_specialtyImmunologyAnti-Inflammatory AgentsLower riskFluticasone propionateIntermittent dosingFluticasone propionateDermatitis Atopiclaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineDouble-Blind MethodRandomized controlled triallaw030225 pediatricsInternal medicineSecondary PreventionmedicineAtopic dermatitis Clinical trial Fluticasone propionate Intermittent dosing PreventionHumansImmunology and AllergyChildFluticasoneAtopic dermatitisBody surface areabusiness.industryPreventionGeneral MedicineAtopic dermatitismedicine.diseaseClinical trialRegimenChild PreschoolRelative riskFluticasoneFemalebusinessmedicine.drug
researchProduct

Polyaspartamide-based nanoparticles loaded with fluticasone propionate and the in vitro evaluation towards cigarette smoke effects

2017

This paper describes the evaluation of polymeric nanoparticles (NPs) as a potential carrier for lung administration of fluticasone propionate (FP). The chosen polymeric material to produce NPs was a copolymer based on α,β-poly(N-2-hydroxyethyl)-d,l-aspartamide (PHEA) whose backbone was derivatised with different molecules, such as poly(lactic acid) (PLA) and polyethylenglycol (PEG). The chosen method to produce NPs from PHEA-PLA-PEG2000 was the method based on high-pressure homogenization and subsequent solvent evaporation by adding Pluronic F68 during the process and trehalose before lyophilisation. Obtained colloidal FP-loaded NPs showed a slightly negative surface charge and nanometric d…

Materials scienceFluticasone propionate (FP)General Chemical EngineeringNanoparticle02 engineering and technologyPolymeric nanoparticle010402 general chemistry01 natural sciencesαβ-poly-(N-2-hydroxyethyl)-DL-aspartamide (PHEA)Articlealpha beta-poly-(N-2-hydroxyethyl)-D L-aspartamide (PHEA)">dPoly(lactic acid) (PLA)lcsh:ChemistryColloidchemistry.chemical_compoundPEG ratioCopolymer?Organic chemistryGeneral Materials ScienceSurface charge?-poly-(N-2-hydroxyethyl)-dαβ-poly-(N-2-hydroxyethyl)-technology industry and agriculture">l-aspartamide (PHEA)Poly(ethylene glycol) (PEG)respiratory system021001 nanoscience & nanotechnologyTrehaloseIn vitro0104 chemical sciencesLactic acidαβ-poly-(<i>N</i>-2-hydroxyethyl)-<span style="font-variant: small-caps;">d</span><span style="font-variant: small-caps;">l</span>-aspartamide (PHEA); poly(lactic acid) (PLA); poly(ethylene glycol) (PEG); polymeric nanoparticles; fluticasone propionate (FP)polymeric nanoparticleschemistrylcsh:QD1-999l-aspartamide (PHEA); poly(lactic acid) (PLA); poly(ethylene glycol) (PEG); polymeric nanoparticles; fluticasone propionate (FP)0210 nano-technologyNuclear chemistry
researchProduct

Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage.

2014

International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studi…

medicine.medical_specialtyCombination therapyAsthma exacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionateAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerAsthma controlFluticasone propionate/formoterolForced Expiratory VolumeFormoterol FumarateInternal MedicineMedicineHumansAnti-Asthmatic AgentsAsthma exacerbationsParticle SizeIntensive care medicineAsthmaFluticasonebusiness.industryInhalerNebulizers and VaporizersFixed-combination therapyAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhaler; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations; Ethanolamines; Fluticasone; Forced Expiratory Volume; Formoterol Fumarate; Humans; Nebulizers and Vaporizers; Particle Size; Quality of Life; Treatment Outcomemedicine.diseaseSingle-aerosol inhalerAsthmaBronchodilator AgentsAndrostadienesDrug CombinationsTreatment OutcomeTolerabilityAsthma control Asthma exacerbations Fixed-combination therapy Fluticasone propionate/formoterol Single-aerosol inhalerEthanolaminesAnesthesiaAsthma exacerbations; Asthma control; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerQuality of LifeFluticasoneFormoterol FumarateFormoterolbusinessmedicine.drugEuropean journal of internal medicine
researchProduct